HALO – Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.HALO
$50.23Name : Halozyme Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,189,390,848.00
EPSttm : 3.76
Halozyme Therapeutics, Inc.
$50.23
24.56%$16.35Float Short %
7.76
Margin Of Safety %
73
Put/Call OI Ratio
0.42
EPS Next Q Diff
0.3
EPS Last/This Y
1.8
EPS This/Next Y
1.44
Price
50.23
Target Price
68.38
Analyst Recom
2.11
Performance Q
-12.38
Relative Volume
8.03
Beta
1.26
Ticker: HALO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | HALO | 61.19 | 0.38 | 0.18 | 8675 |
| 2025-04-15 | HALO | 61.28 | 0.32 | 0.10 | 10299 |
| 2025-04-16 | HALO | 58.78 | 0.32 | 1.19 | 10337 |
| 2025-04-17 | HALO | 58.79 | 0.32 | 0.12 | 10428 |
| 2025-04-18 | HALO | 58.79 | 0.32 | 0.12 | 10428 |
| 2025-04-21 | HALO | 57.31 | 0.27 | 0.87 | 9174 |
| 2025-04-22 | HALO | 58.19 | 0.27 | 0.11 | 9211 |
| 2025-04-23 | HALO | 58.4 | 0.27 | 0.57 | 9262 |
| 2025-04-24 | HALO | 59.24 | 0.28 | 0.92 | 9379 |
| 2025-04-25 | HALO | 60.49 | 0.29740383308414 | 0.36942675159236 | 9545 |
| 2025-04-28 | HALO | 60.57 | 0.29950528145474 | 1.4090909090909 | 9719 |
| 2025-04-29 | HALO | 60.82 | 0.33 | 0.83 | 9964 |
| 2025-04-30 | HALO | 61.4 | 0.34 | 1.82 | 10133 |
| 2025-05-01 | HALO | 60.03 | 0.34 | 3.51 | 10150 |
| 2025-05-02 | HALO | 61.2 | 0.36 | 0.58 | 10341 |
| 2025-05-05 | HALO | 60.58 | 0.36 | 1.79 | 10412 |
| 2025-05-06 | HALO | 61.99 | 0.37 | 1.78 | 10545 |
| 2025-05-07 | HALO | 70.05 | 0.41 | 0.24 | 11030 |
| 2025-05-08 | HALO | 67.68 | 0.38 | 0.49 | 12290 |
| 2025-05-09 | HALO | 65.84 | 0.39 | 0.24 | 12473 |
| 2025-05-12 | HALO | 66.58 | 0.39 | 0.66 | 12694 |
| 2025-05-13 | HALO | 50.2 | 0.42 | 0.24 | 13265 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | HALO | 61.39 | 21.7 | - | 4.90 |
| 2025-04-15 | HALO | 61.28 | 21.7 | - | 4.90 |
| 2025-04-16 | HALO | 58.84 | 21.7 | - | 4.90 |
| 2025-04-17 | HALO | 58.79 | 21.7 | - | 4.90 |
| 2025-04-18 | HALO | 58.79 | 21.7 | - | 4.90 |
| 2025-04-21 | HALO | 57.33 | 21.7 | - | 4.90 |
| 2025-04-22 | HALO | 58.21 | 18.5 | - | 5.00 |
| 2025-04-23 | HALO | 58.41 | 18.5 | - | 5.00 |
| 2025-04-24 | HALO | 59.29 | 18.5 | - | 5.00 |
| 2025-04-25 | HALO | 60.49 | 18.5 | - | 5.00 |
| 2025-04-28 | HALO | 60.57 | 18.5 | - | 5.00 |
| 2025-04-29 | HALO | 60.82 | 18.5 | - | 5.00 |
| 2025-04-30 | HALO | 61.42 | 18.5 | - | 5.00 |
| 2025-05-01 | HALO | 60.08 | 18.5 | - | 5.00 |
| 2025-05-02 | HALO | 61.19 | 18.5 | - | 5.00 |
| 2025-05-05 | HALO | 60.58 | 18.5 | - | 5.00 |
| 2025-05-06 | HALO | 59.37 | 18.5 | - | 5.00 |
| 2025-05-07 | HALO | 70.14 | 18.5 | - | 5.00 |
| 2025-05-08 | HALO | 67.62 | 27.5 | - | 5.00 |
| 2025-05-09 | HALO | 65.84 | 31.5 | - | 5.29 |
| 2025-05-12 | HALO | 66.58 | 31.5 | - | 5.29 |
| 2025-05-13 | HALO | 50.23 | 31.5 | - | 5.29 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | HALO | -4.53 | -2.32 | 7.55 |
| 2025-04-15 | HALO | -4.53 | -2.32 | 7.55 |
| 2025-04-16 | HALO | -4.53 | -2.32 | 7.55 |
| 2025-04-17 | HALO | -3.12 | -2.32 | 7.55 |
| 2025-04-18 | HALO | -3.12 | -2.32 | 7.55 |
| 2025-04-21 | HALO | -3.12 | -0.91 | 7.55 |
| 2025-04-22 | HALO | -3.12 | -0.91 | 7.55 |
| 2025-04-23 | HALO | -3.12 | -0.91 | 7.55 |
| 2025-04-24 | HALO | -3.12 | -0.91 | 7.55 |
| 2025-04-25 | HALO | -3.12 | -0.91 | 7.55 |
| 2025-04-28 | HALO | -3.12 | -1.24 | 7.87 |
| 2025-04-29 | HALO | -3.44 | -1.24 | 7.87 |
| 2025-04-30 | HALO | -3.44 | -1.24 | 7.87 |
| 2025-05-01 | HALO | -3.44 | -1.24 | 7.87 |
| 2025-05-02 | HALO | -3.44 | -1.24 | 7.87 |
| 2025-05-05 | HALO | -3.44 | -1.65 | 7.87 |
| 2025-05-06 | HALO | -3.44 | -1.65 | 7.87 |
| 2025-05-07 | HALO | -3.44 | -1.65 | 7.87 |
| 2025-05-08 | HALO | -3.44 | -1.65 | 7.87 |
| 2025-05-09 | HALO | -3.45 | -1.65 | 7.89 |
| 2025-05-12 | HALO | -3.33 | -1.19 | 7.76 |
| 2025-05-13 | HALO | -3.33 | -1.19 | 7.76 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.11
Avg. EPS Est. Current Quarter
1.2
Avg. EPS Est. Next Quarter
1.41
Insider Transactions
-3.33
Institutional Transactions
-1.19
Beta
1.26
Average Sales Estimate Current Quarter
282
Average Sales Estimate Next Quarter
331
Fair Value
86.78
Quality Score
97
Growth Score
95
Sentiment Score
87
Actual DrawDown %
28.8
Max Drawdown 5-Year %
-49.1
Target Price
68.38
P/E
13.33
Forward P/E
7.01
PEG
0.46
P/S
5.71
P/B
12.83
P/Free Cash Flow
12.48
EPS
3.77
Average EPS Est. Cur. Y
5.29
EPS Next Y. (Est.)
6.74
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
44.76
Relative Volume
8.03
Return on Equity vs Sector %
77
Return on Equity vs Industry %
93.9
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.39
EBIT Estimation
Halozyme Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 350
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
stock quote shares HALO – Halozyme Therapeutics, Inc. Stock Price stock today
news today HALO – Halozyme Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch HALO – Halozyme Therapeutics, Inc. yahoo finance google finance
stock history HALO – Halozyme Therapeutics, Inc. invest stock market
stock prices HALO premarket after hours
ticker HALO fair value insiders trading